Automating MS-Based Biotherapeutic Characterization Workflows for Developability Assessment

Gaining a comprehensive overview of biopharmaceutical candidates’ molecular characteristics for developability assessments typically requires collation of data obtained using multiple instruments and software platforms across several labs. Processing these large and often disparate data sets can create data processing bottlenecks due to the laborious, time-intensive, and error-prone nature of manual data management.
You’ll see how Genedata integrates biologics formulation software, high‑resolution sequence‑structural analysis software, and scalable developability screening software to streamline characterization across antibodies, multispecifics, and complex modalities. With native support for antibody informatics, ADC development, and comprehensive in silico screening software, the platform enables scientists to rapidly evaluate PTMs, heterogeneity, and other critical quality attributes.

The session also demonstrates how AI-driven developability prediction software, generative AI protein design software, and advanced analytics operationalize AI in drug development, allowing teams to interpret MS data more efficiently and connect it directly to broader drug discovery and development decisions. As part of an integrated developability assessment platform, Genedata empowers organizations to automate MS characterization at scale, reduce manual effort, and accelerate the delivery of high‑quality biotherapeutics.

Discover how scientists at Novartis are leveraging automated MS data workflows to:

• Improve productivity by reducing analysis time from days to hours
• Harmonize data analysis to enable meaningful comparison of results
• Eliminate error-prone manual data management
• Facilitate collaboration through an integrated MS data processing platform

Learning Objectives

• Gain insights into the logistical and analytical challenges presented by emerging biotherapeutic modalities
• Learn how mass spectrometry and automation can address these and other key biopharma industry challenges
• Explore how fully automated MS-based protein analysis supports next-generation biotherapeutic development

Who Should Watch

Biopharma analytical scientists and managers who are looking to automate mass spectrometry-based analytical workflows for characterization and quality monitoring of biotherapeutics.

Presenters

• Christian Hug, M.Sc., Senior Scientist, Novartis AG
• Jonathan Jones, Ph.D., Business Development, Genedata